Dr. Dwight Owen, MD
Claim this profileOhio State University Comprehensive Cancer Center
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
19 drugs studied
Area of expertise
1Lung Cancer
Global LeaderStage IV
EGFR positive
Stage I
2Non-Small Cell Lung Cancer
Stage IV
EGFR positive
Stage I
Affiliated Hospitals
Clinical Trials Dwight Owen, MD is currently running
Vismodegib + Atezolizumab
for Lung Cancer
This phase Ib trial tests the safety, side effects, and best dose of the combination of vismodegib and atezolizumab in treating patients with non-small cell lung cancer (NSCLC) that has come back after a period of improvement (recurrent) or has spread from where it first started (primary site) to other places in the body (metastatic). Vismodegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving a combination of vismodegib and atezolizumab may be safe, tolerable and/or effective than either drug alone in treating patients with recurrent or metastatic NSCLC.
Recruiting1 award Phase 16 criteria
Temozolomide + Atezolizumab
for Small Cell Lung Cancer
This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving temozolomide and atezolizumab as second or third line treatment may help prolong survival in patients with small cell lung cancer.
Recruiting1 award Phase 215 criteria
More about Dwight Owen, MD
Clinical Trial Related1 year of experience running clinical trials · Led 13 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Dwight Owen, MD has experience with
- Atezolizumab
- Pembrolizumab
- Carboplatin
- Vismodegib
- Temozolomide
- Nivolumab
Breakdown of trials Dwight Owen, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Skin Cancer
Solid Tumors
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dwight Owen, MD specialize in?
Dwight Owen, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are EGFR positive.
Is Dwight Owen, MD currently recruiting for clinical trials?
Yes, Dwight Owen, MD is currently recruiting for 8 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Dwight Owen, MD has studied deeply?
Yes, Dwight Owen, MD has studied treatments such as Atezolizumab, Pembrolizumab, Carboplatin.
What is the best way to schedule an appointment with Dwight Owen, MD?
Apply for one of the trials that Dwight Owen, MD is conducting.
What is the office address of Dwight Owen, MD?
The office of Dwight Owen, MD is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.